vs
Side-by-side financial comparison of Hologic (HOLX) and SouthState Bank Corp (SSB). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $661.7M, roughly 1.6× SouthState Bank Corp). SouthState Bank Corp runs the higher net margin — 34.1% vs 17.1%, a 17.0% gap on every dollar of revenue. Over the past eight quarters, SouthState Bank Corp's revenue compounded faster (37.4% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
SouthState Bank, based in Winter Haven, Florida, is an American bank and a subsidiary of SouthState Corporation, a bank holding company. As of May 26, 2025, the company had 371 branches in South Carolina, North Carolina, Georgia, Florida, Alabama, Virginia, Colorado and Texas.
HOLX vs SSB — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $661.7M |
| Net Profit | $179.1M | $225.8M |
| Gross Margin | 56.0% | — |
| Operating Margin | 22.6% | 15.1% |
| Net Margin | 17.1% | 34.1% |
| Revenue YoY | 2.5% | — |
| Net Profit YoY | -10.9% | 153.5% |
| EPS (diluted) | $0.79 | $2.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $661.7M | ||
| Q4 25 | $1.0B | $581.1M | ||
| Q3 25 | $1.0B | $599.7M | ||
| Q2 25 | $1.0B | $577.9M | ||
| Q1 25 | $1.0B | $544.5M | ||
| Q4 24 | $1.0B | $369.8M | ||
| Q3 24 | $988.0M | $351.5M | ||
| Q2 24 | $1.0B | $350.3M |
| Q1 26 | — | $225.8M | ||
| Q4 25 | $179.1M | $247.7M | ||
| Q3 25 | $187.2M | $246.6M | ||
| Q2 25 | $194.9M | $215.2M | ||
| Q1 25 | $-17.4M | $89.1M | ||
| Q4 24 | $201.0M | $144.2M | ||
| Q3 24 | $178.6M | $143.2M | ||
| Q2 24 | $194.5M | $132.4M |
| Q1 26 | — | — | ||
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — |
| Q1 26 | — | 15.1% | ||
| Q4 25 | 22.6% | 54.3% | ||
| Q3 25 | 22.6% | 53.6% | ||
| Q2 25 | 24.9% | 48.8% | ||
| Q1 25 | -0.7% | 22.3% | ||
| Q4 24 | 22.5% | 50.7% | ||
| Q3 24 | 23.3% | 53.1% | ||
| Q2 24 | 24.1% | 49.3% |
| Q1 26 | — | 34.1% | ||
| Q4 25 | 17.1% | 42.6% | ||
| Q3 25 | 17.8% | 41.1% | ||
| Q2 25 | 19.0% | 37.2% | ||
| Q1 25 | -1.7% | 16.4% | ||
| Q4 24 | 19.7% | 39.0% | ||
| Q3 24 | 18.1% | 40.7% | ||
| Q2 24 | 19.2% | 37.8% |
| Q1 26 | — | $2.28 | ||
| Q4 25 | $0.79 | $2.47 | ||
| Q3 25 | $0.84 | $2.42 | ||
| Q2 25 | $0.86 | $2.11 | ||
| Q1 25 | $-0.08 | $0.87 | ||
| Q4 24 | $0.87 | $1.88 | ||
| Q3 24 | $0.75 | $1.86 | ||
| Q2 24 | $0.82 | $1.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $2.9B |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $5.2B | $9.0B |
| Total Assets | $9.2B | $68.0B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $2.9B | ||
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.4B | — |
| Q1 26 | — | — | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — |
| Q1 26 | — | $9.0B | ||
| Q4 25 | $5.2B | $9.1B | ||
| Q3 25 | $5.0B | $9.0B | ||
| Q2 25 | $4.8B | $8.8B | ||
| Q1 25 | $4.6B | $8.6B | ||
| Q4 24 | $4.8B | $5.9B | ||
| Q3 24 | $5.1B | $5.9B | ||
| Q2 24 | $5.0B | $5.7B |
| Q1 26 | — | $68.0B | ||
| Q4 25 | $9.2B | $67.2B | ||
| Q3 25 | $9.0B | $66.0B | ||
| Q2 25 | $8.8B | $65.9B | ||
| Q1 25 | $8.5B | $65.1B | ||
| Q4 24 | $8.7B | $46.4B | ||
| Q3 24 | $9.2B | $46.1B | ||
| Q2 24 | $8.9B | $45.5B |
| Q1 26 | — | — | ||
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | — |
| Free Cash FlowOCF − Capex | $215.2M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | 1.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $229.9M | $232.1M | ||
| Q3 25 | $355.1M | $122.4M | ||
| Q2 25 | $343.3M | $72.6M | ||
| Q1 25 | $169.4M | $-126.3M | ||
| Q4 24 | $189.3M | $354.3M | ||
| Q3 24 | $367.0M | $-246.8M | ||
| Q2 24 | $405.8M | $126.8M |
| Q1 26 | — | — | ||
| Q4 25 | $215.2M | $215.5M | ||
| Q3 25 | $341.4M | $101.7M | ||
| Q2 25 | $330.5M | $52.5M | ||
| Q1 25 | $153.9M | $-139.1M | ||
| Q4 24 | $172.5M | $340.9M | ||
| Q3 24 | $350.6M | $-254.2M | ||
| Q2 24 | $385.3M | $117.3M |
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | 37.1% | ||
| Q3 25 | 32.5% | 17.0% | ||
| Q2 25 | 32.3% | 9.1% | ||
| Q1 25 | 15.3% | -25.5% | ||
| Q4 24 | 16.9% | 92.2% | ||
| Q3 24 | 35.5% | -72.3% | ||
| Q2 24 | 38.1% | 33.5% |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 2.9% | ||
| Q3 25 | 1.3% | 3.5% | ||
| Q2 25 | 1.3% | 3.5% | ||
| Q1 25 | 1.5% | 2.4% | ||
| Q4 24 | 1.6% | 3.6% | ||
| Q3 24 | 1.7% | 2.1% | ||
| Q2 24 | 2.0% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | 0.94× | ||
| Q3 25 | 1.90× | 0.50× | ||
| Q2 25 | 1.76× | 0.34× | ||
| Q1 25 | — | -1.42× | ||
| Q4 24 | 0.94× | 2.46× | ||
| Q3 24 | 2.05× | -1.72× | ||
| Q2 24 | 2.09× | 0.96× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
SSB
| Net Interest Income | $561.6M | 85% |
| Noninterest Income | $100.1M | 15% |
